In the present studies, we used a VEGF independent tumour model of RCC (VEGF-R negative) to evaluate the in vitro and in vivo efficacy of a different VEGF antisense PS-ODNs sequence (V515). The gene discussed is VEGFA; the disease is renal cell carcinoma.